Edition:
India

Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

28.25USD
17 Jan 2018
Change (% chg)

$0.70 (+2.54%)
Prev Close
$27.55
Open
$28.50
Day's High
$29.50
Day's Low
$28.05
Volume
292,777
Avg. Vol
102,178
52-wk High
$30.85
52-wk Low
$11.80

Chart for

About

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or... (more)

Overall

Beta: --
Market Cap(Mil.): $495.06
Shares Outstanding(Mil.): 30.56
Dividend: --
Yield (%): --

Financials

BRIEF-Atara Biotherapeutics Gets FDA Clearance To Proceed With Multiple Sclerosis study

* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH ENROLLMENT AT U.S. SITES FOR ONGOING GLOBAL PHASE 1 CLINICAL STUDY TO EVALUATE ATA188 IN PATIENTS WITH PROGRESSIVE OR RELAPSING-REMITTING MULTIPLE SCLEROSIS

10 Jan 2018

BRIEF-Camber Capital Management Reports 6.7 Pct Passive Stake In Atara Biotherapeutics

* CAMBER CAPITAL MANAGEMENT LLC REPORTS A 6.7 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS AS OF JANUARY 04 - SEC FILING Source text : ( http://bit.ly/2m1PfiG ) Further company coverage:

05 Jan 2018

BRIEF-Atara Biotherapeutics Announces Proposed Offering Of Common Stock

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

03 Jan 2018

BRIEF-Atara Biotherapeutics Gets FDA Clearance To Initiate Two Phase 3 Clinical Studies To Evaluate Tabelecleucel

* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO INITIATE TWO PHASE 3 CLINICAL STUDIES TO EVALUATE TABELECLEUCEL IN PATIENTS WITH RITUXIMAB-REFRACTORY EPSTEIN-BARR VIRUS ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (EBV+PTLD)

29 Dec 2017

BRIEF-Morgan Stanley Reports 5 Pct Passive Stake In Atara Biotherapeutics As Of Nov 27

* MORGAN STANLEY REPORTS 5.0 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS INC AS OF NOVEMBER 27 - SEC FILING Source text: (http://bit.ly/2jrEZiq) Further company coverage:

08 Dec 2017

BRIEF-Atara Biotherapeutics reports Q3 loss per share $1.02

* Atara Biotherapeutics Inc announces third quarter 2017 financial results and recent highlights

09 Nov 2017

BRIEF-Atara Biotherapeutics receives rare pediatric disease designation from FDA for Ata230

* Atara Biotherapeutics receives rare pediatric disease designation from FDA for Ata230 for treatment of congenital cytomegalovirus (CMV) infection Source text for Eikon: Further company coverage:

26 Oct 2017

BRIEF-Atara Biotherapeutics announces abstract publication for two MSParis2017 congress presentations

* Atara Biotherapeutics announces abstract publication for two MSParis2017 congress presentations, including updated interim results from a phase 1 study of autologous ATA190 in patients with progressive multiple sclerosis (MS)

16 Oct 2017

BRIEF-Atara Biotherapeutics Inc - ‍announced receipt of positive regulatory feedback from Health Canada for ATA129​

* Atara Biotherapeutics Inc - ‍announced receipt of positive regulatory feedback from Health Canada for ATA129​

11 Sep 2017

BRIEF-Atara Biotherapeutics receives FDA orphan drug designation for ATA230

* Atara Biotherapeutics receives FDA orphan drug designation for ata230

05 Sep 2017

Competitors

Earnings vs. Estimates